Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

Monte Rosa Therapeutics (GLUE) will present MRT-8102 GFORCE-1 Phase 1 study results during a webcast on October 1, 2026.

Rhea-AI Summary

Monte Rosa Therapeutics (GLUE) will present MRT-8102 GFORCE-1 Phase 1 study results during a webcast on October 1, 2026. The presentation begins at 8:00 a.m. ET and covers subjects with elevated cardiovascular disease risk. It will review safety and activity data across multiple dose levels following 4 weeks of treatment, including effects on drivers of atherosclerotic cardiovascular disease.

Argus 15 min delay 7 alerts

+6.04% vs previous close $12.65 last price 0.7x rel. volume Open Argus

Details

Market move: GLUE +6.04% vs previous close. Phase 1 MRT-8102 clinical data

$10.50 – $13.03 Day Range

$1.08B Market Cap

On Sep 30, the day this news came out, the latest delayed price for GLUE is 6.04% above the previous close. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $12.65.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Presentation time: 8:00 a.m. ET on Oct. 1, 2026 Treatment duration: 4 weeks

Presentation time

8:00 a.m. ET on Oct. 1, 2026

GFORCE-1 Phase 1 results presentation

Treatment duration

4 weeks

MRT-8102 safety and activity data across multiple dose levels

Previous Clinical trial Reports

1 past event · Latest: Jan 07

Same Type 1 event

1. Jan 07

   Phase 1 data

   24h Move

   +45.4%

   Interim MRT-8102 results reported hsCRP reductions and NEK7 degradation in elevated CVD-risk subjects.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

molecular glue degrader, atherosclerotic cardiovascular disease

2 terms

molecular glue degrader technical

"developing novel molecular glue degrader (MGD)-based medicines"

A molecular glue degrader is a small drug-like molecule that acts like a tiny adhesive, sticking a specific disease-related protein to the cell’s natural disposal machinery so the protein is destroyed rather than merely blocked. Investors watch these compounds because they can turn previously untreatable targets into removable liabilities, potentially creating breakthrough therapies, shifting development risk, and offering strong commercial upside if clinical results and regulatory approval follow.

atherosclerotic cardiovascular disease medical

"multiple pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD)"

Atherosclerotic cardiovascular disease is the chronic narrowing and hardening of arteries caused by buildup of fatty plaques, like pipes gradually clogged by residue, which reduces blood flow to the heart, brain and other organs. It matters to investors because it is a leading driver of demand for drugs, medical devices, diagnostics and long‑term care—and outcomes from clinical trials, approvals or changes in treatment guidelines can quickly affect the market value of companies serving this large, costly area of medicine.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk. The presentation will include safety and activity data for MRT-8102 across multiple dose levels following 4 weeks of treatment and will showcase pioneering data on the modulation of multiple pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) by MRT-8102.

A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com